Baricitinib added to clot removal treatment for stroke caused by a blocked brain artery
Tests baricitinib alongside clot removal in adults with a large-artery stroke.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
Key facts
- Where
- Hefei, ChinaSee the site
- Phase
- Phase 2/3
Where in China
- The First Affiliated Hospital of University of Science and Technology of China, Hefei, RecruitingHefei, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of University of Science and Technology of China
- Trial code
- NCT07449910
- Record updated
- 4 March 2026
- Original description
The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.Read full original descriptionShow less
Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial
The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.
Inclusion: Age is 18 years old or above; Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA; Randomized within 24h after the onset; The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination; The mTICI score after endovascular treatment (EVT) is above 2b; informed consent.
Exclusion: Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, and unable to be controlled by oral antihypertensive drugs; Previous history of diagnosed viral hepatitis and tuberculosis; Intracranial hemorrhage confirmed by CT or MRI; Allergic to contrast agents; Allergic to baricitinib or having contraindications for using baricitinib; Recent history of using other JAK inhibitors or potent immunosuppressants, including but not limited to the combined use with potent immunosuppressive drugs such as azathioprine, tacrolimus, tofacitinib and fedratinib, etc. Tortuous arteries make the thrombectomy device unable to reach the target blood vessel; Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR >1.7; Hemoglobin value <8g/L; mRS score>2 for patients <80 years, or mRS score>1 for those ≥80 years before onset; Pregnant or lactating women; Participating in other clinical studies.